Minimal dose for effective clinical outcome and predictive factors for responsiveness to carvedilol: Japanese chronic heart failure (J-CHF) study

International Journal of Cardiology

Volumn 164, Issue 2, 2013, Pages 238-244

  Okamoto, Hiroshi ^a   Hori, Masatsugu ^b   Matsuzaki, Masunori ^c   Tsutsui, Hiroyuki ^d   Yamazaki, Tsutomu ^e   Nagai, Ryozo ^f   Yoshikawa, Tsutomu ^g   Fujio, Yasushi ^h   Nonen, Shinpei ⁱ   Azuma, Junichi ⁱ   Izumi, Tohru ^j   Ohashi, Yasuo ^k   Kitabatake, Akira ^d  

^a HOKKAIDO MEDICAL CENTER   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f JICHI MEDICAL UNIVERSITY   (Japan)

^g SAKAKIBARA HEART INSTITUTE   (Japan)

^h OSAKA UNIVERSITY   (Japan)

ⁱ HYOGO COLLEGE OF MEDICINE   (Japan)

^j KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k UNIVERSITY OF TOKYO   (Japan)

more..

Author keywords

Brain natriuretic peptide; Carvedilol; Heart failure; Heart rate; Keywords; Osteopontin

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; OSTEOPONTIN;

ADULT; ARTICLE; BRADYCARDIA; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE SEVERITY; DNA POLYMORPHISM; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GENE DELETION; GENETIC MARKER; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HOSPITALIZATION; HUMAN; HUMAN CELL; HYPOTENSION; JAPANESE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEW YORK HEART ASSOCIATION CLASS; OSTEOPONTIN GENE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TACHYCARDIA; TREATMENT OUTCOME; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PARAMETERS; DRUG MEGADOSE; DRUG TOLERABILITY; HEART FAILURE; HEART LEFT VENTRICLE DIASTOLIC DIAMETER; INTENTION TO TREAT ANALYSIS; JAPANESE (PEOPLE); OPN GENE; RESTING HEART RATE; RISK REDUCTION; TREATMENT WITHDRAWAL;

ADRENERGIC BETA-ANTAGONISTS; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARBAZOLES; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPANOLAMINES; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84875215477     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.11.051     Document Type: Article

References (30)

1. MERIT-HF Study Group Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 353 1999 2001 2007
2. M. Packer, A.J. Coats, and M.B. Fowler Effect of carvedilol on survival in severe chronic heart failure N Engl J Med 344 2001 1651 1658
3. M. Jessup, W.T. Abraham, and D.E. Casey 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation Circulation 119 2009 1977 2016
4. J.J.V. McMurray, S. Adamopoulos, and S.D. Anker ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC Eur Heart J 33 2012 1787 1847
5. M. Ansari, M.G. Shlipak, and P.A. Heidenreich Improving guideline adherence: a randomized trial evaluating strategies to increase beta-blocker use in heart failure Circulation 107 2003 2799 2804
6. J.G. Cleland, A. Cohen-Solal, and J.C. Aguilar Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey Lancet 360 2002 1631 1639
7. G.C. Fonarow, W.T. Abraham, and N.M. Albert Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from organized program to initiate lifesaving treatment in hospitalized patients with heart failure) Am J Cardiol 102 2008 1524 1529
8. M. Hori, S. Sasayama, and A. Kitabatake Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial Am Heart J 147 2004 324 330
9. M. Matsuzaki, M. Ishii, and T. Izumi Guidelines for treatment of chronic heart failure (JCS 2010) Available at: http://www.j-circ.or.jp/guideline/pdf/ JCS2010-matsuzaki-d.pdf [Japanese, Accessed Dec 5, 2011]
10. T. Ogihara, Y. Goto, and K. Yoshinaga Dose-effect relationship of carvedilol in essential hypertension: an open study Drugs 36 1988 75 81
11. Japanese Beta-Blockers and Calcium Antagonists Myocardial Infarction (JBCMI) Investigators Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects Am J Cardiol 93 2004 969 973
12. M.R. Bristow, E.M. Gilbert, and W.T. Abraham Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA investigators Circulation 94 1996 2807 2816
13. F.A. McAlister, N. Wiebe, and M. PStat Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure Ann Intern Med 150 2009 784 794
14. J. Kjekshus Is there a heart rate paradox - demystification of the myths? J Intern Med 266 2009 242 247
15. K. Swedberg, M. Komajda, and M. Böhm Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study Lancet 376 2010 875 885
16. M. Böhm, K. Swedberg, and M. Komajda Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomized placebo-controlled trial Lancet 376 2010 886 894
17. A.J. Wood Racial differences in the response to drugs: pointers to genetic differences N Engl J Med 344 2001 1393 1396
18. S.B. Liggett, J. Mialet-Perez, and S. Thaneemit-Chen A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure Proc Natl Acad Sci U S A 103 2006 11288 11293
19. M. Fiuzat, D. Wojdyla, and D. Kitzman Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction J Am Coll Cardiol 60 3 2012 208 215
20. J. Wikstrand, A. Hjalmarson, and F. Waagstein Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure. Analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF) J Am Coll Cardiol 40 2002 491 498
21. P. Lechat, J.S. Hulot, and S. Escolano Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial Circulation 103 2001 1428 1433
22. F. Hartmann, M. Packer, and A.J. Coats Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial Circulation 110 2004 1780 1786
23. M. Komajda, B. Lutiger, and H. Madeira Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodeling Mild CHF EvaluatioN) Eur J Heart Fail 6 2004 467 475
24. The Beta-Blocker Evaluation of Survival Trial Investigators A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure N Engl J Med 344 2001 1659 1667
25. S. Nonen, H. Okamoto, and M. Akino No positive association between adrenergic receptor variants of alpha2cDel322-325, beta1Ser49, beta1Arg389 and the risk for heart failure in the Japanese population Br J Clin Pharmacol 60 2005 414 417
26. M.R. Bristow, H. Krause-Steinrauf, and R. Nuzzo Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial Circulation 110 2004 1437 1442
27. P. Stawowy, F. Blaschke, and P. Pfautsch Increased myocardial expression of osteopontin in patients with advanced heart failure Eur J Heart Fail 4 2002 139 146
28. K. Singh, G. Sirokman, and C. Communal Myocardial osteopontin expression coincides with the development of heart failure Hypertension 33 1999 663 670
29. F. Giacopelli, R. Marciano, and A. Pistorio Polymorphisms in the osteopontin promoter affects its transcriptional activity Physiol Genomics 20 2004 87 96
30. T. Yamada, M. Fukunami, and M. Ohmori Which subgroup of patients with dilated cardiomyopathy would benefit from long-term beta-blocker therapy? A histologic viewpoint J Am Coll Cardiol 21 1993 628 633